Pfizer Inc.’s oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized Covid-19 patients with pneumonia in Brazil, meeting the study’s main goal.

An investigational oral MK2 inhibitor from clinical-stage biopharmaceutical company Aclaris Therapeutics was safe and associated with promising reductions in inflammatory markers in a 12-week, Phase II study of patients with moderate to severe rheumatoid arthritis (RA).

A little more than one year after Gilead Sciences Inc. and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies pulled the plug on that goal as well as others following a Complete Response Letter issued in August 2020.

Genentech is eliminating 474 employees, mostly based out of the company’s South San Francisco facilities, with the job cuts expected to be permanent.

GlaxoSmithKline started a trial to test an experimental rheumatoid arthritis drug on patients suffering from COVID-19 related pneumonia.

Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?

China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.

AbbVie’s Rinvoq was approved by the FDA for treating adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

Gilead Sciences Inc. and Galapagos NV announced that the Marketing Authorization Application for filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis – was validated and is under evaluation by the European Medicines Agency.

Four months after reporting success in two rheumatoid arthritis trials with developmental partner Galapagos NV, Gilead Sciences Inc. is strengthening that partnership with a 10-year global research and development collaboration worth more than $5 billion. Gilead is also increasing the company’s stake in Galapagos.